This issue follows two treatments at very different stages. Tavapadon, described in News #2 while it was awaiting a decision, has now been approved in the US. The ACI-7104 vaccine described in News #4 has additional follow-up data, but those data do not yet show that it helps people with Parkinson’s feel or move better. An approval and an immune-response result should not be read as equivalent breakthroughs.
Tavapadon becomes an approved treatment for adults in the US
🔍 What happened
The US Food and Drug Administration listed tavapadon (brand name Juvmo) as approved for adult Parkinson’s disease on September 25, 2026. It is a once-daily tablet studied both alone and alongside levodopa. Tavapadon stimulates the brain’s D1 and D5 dopamine receptors. That is a different receptor pattern from some older dopamine agonists, but different does not automatically mean safer or better for every person. A dopamine agonist is a medicine that imitates part of dopamine’s signaling; its suitability still depends on symptoms, other medicines and adverse effects.
One trial behind the approval, TEMPO-3, enrolled 507 people whose symptoms fluctuated despite levodopa. After roughly 26 weeks, time spent moving reasonably well without troublesome involuntary movements had increased by 1.7 hours a day on average in those adding tavapadon, compared with 0.6 hours in those adding placebo: a difference of about 1.1 hours. This is an average across trial participants, not a promise of an extra 1.1 good hours for every person. Other trials in earlier Parkinson’s disease also found better daily-function and movement scores than placebo when tavapadon was used without levodopa.
✅ If you live with Parkinson’s
The change is that tavapadon is an approved US option rather than only an investigational medicine. Approval in the US does not establish approval, supply or reimbursement elsewhere. Nor was it approved as a cure or a treatment proven to stop Parkinson’s progression: its role is symptom control.
If you take levodopa but still have periods when it wears off, tell your clinician when those periods start, how long they last and which activities become difficult. Deciding whether another medicine fits you also requires considering dizziness, sleepiness, hallucinations, involuntary movements and your current doses. Nausea, dizziness, hallucinations, a drop in blood pressure on standing and dyskinesia were among the problems reported in trial and manufacturer safety information. Do not change or stop existing medicines based on a news article.
🙋 If you are a care partner
Over several days, note medication times alongside wearing-off periods, difficulty moving and near-falls. After any treatment adjustment, watch for unusual sleepiness, seeing things that are not there, marked dizziness on standing or more unwanted movements. Report new changes to the prescribing clinician rather than adjusting doses yourselves.
Vaccine trial found antibodies, not yet proof of better symptoms
🔍 What happened
On September 23, developer AC Immune reported follow-up through week 100 from the first part of its phase 2 VacSYn study. This is the ACI-7104 vaccine mentioned in News #4. Thirty-four people with early Parkinson’s were assigned at random: 25 received the vaccine and nine placebo. The main purpose of this first part was to assess safety and whether an immune response developed.
The vaccine is designed to prompt the body to make antibodies against abnormal clumps of alpha-synucleinA protein found in nerve cells. Its abnormal clumps are a major research target in Parkinson's, but therapies against it still need clinical testing.Learn more. According to the company, all 25 vaccinated participants developed an antibody response after three immunizations, and antibodies were also observed in cerebrospinal fluid. The announcement did not identify a major safety problem. These findings indicate that the intended biological response occurred and justify further study.
But an antibody response is not the same outcome as less tremor, better walking or slower disease progression. The company states that this 34-person part was not designed to establish clinical or biomarker effects. Exploratory signals cannot settle whether the vaccine changes the course of Parkinson’s, particularly with only nine placebo recipients. Larger comparisons that measure how people with Parkinson’s actually do are still needed.
✅ If you live with Parkinson’s
This is not evidence that a Parkinson’s vaccine has been shown to slow the disease. Researchers have established a biological response, not a benefit you can yet expect to feel. ACI-7104 is investigational, not a routine vaccination or a treatment you can currently request from a pharmacy. These results are not a reason to change medication, exercise or rehabilitation plans.
🙋 If you are a care partner
The word “vaccine” can sound like a standard preventive shot. Explain that this is still a clinical trial treatment and that the next studies must examine outcomes that matter to people with Parkinson’s. If your family is interested in a trial, discuss eligibility, time since diagnosis and current treatment with the care team first.
What you can do now
These two stories are at different stages: tavapadon is approved for symptom treatment in the US, while ACI-7104 is still being tested for clinical benefit. Bring a record of wearing-off times and any new adverse effects to your next appointment. Do not start, stop or change medicine based on these announcements alone.
ParkinON summarized FDA materials, clinical research and developer announcements available by October 1, 2026 in plain language. This is not medical diagnosis or treatment advice. US approval does not establish approval or availability in your country. Discuss treatment decisions with your clinician.